Get the Stockscreener App
0.577
2.89%
-0.0141
Verrica Pharmaceuticals Inc stock is traded at $0.577, with a volume of 42,158.
It is down -2.89% in the last 24 hours and down -22.10% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.5911
Open:
$0.5804
24h Volume:
42,158
Relative Volume:
0.10
Market Cap:
$52.10M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-0.3925
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-5.59%
1M Performance:
-22.10%
6M Performance:
-70.86%
1Y Performance:
-88.29%
1-Day Range:
$0.5529
$0.59
1-Week Range:
$0.54
$0.6751
52-Week Range:
$0.54
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.5707 | 52.10M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
507.77 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.18 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.43 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.07 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.51 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC - Defense World
Brookline Capital Management Comments on VRCA Q1 Earnings - Defense World
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MyChesCo
GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News
Verrica Pharmaceuticals stock hits 52-week low at $0.57 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals stock hits 52-week low at $0.57 - Investing.com India
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com Australia
Strategic Growth and Market Positioning Drive Buy Rating for Verrica Pharmaceuticals - TipRanks
Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - Nasdaq
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Yahoo Finance
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlig - GuruFocus.com
Verrica Pharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c) - TipRanks
Verrica Pharmaceuticals Inc. SEC 10-K Report - TradingView
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Holdings Raised by Rhumbline Advisers - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MyChesCo
Common Warts Clinical and Non-Clinical Studies, Key Companies, - openPR
Verrica Pharmaceuticals Announces Q4 & Full Year 2024 Financial Results Webcast - MyChesCo
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 - The Manila Times
When Will Verrica Pharmaceuticals Release Its 2024 Financial Results? - StockTitan
Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference - MSN
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Verrica Pharmaceuticals stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.61 - Investing.com
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Can Verrica Pharmaceuticals' CEO Presentation Reveal New Growth Strategies at TD Cowen Conference? - StockTitan
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston - The Manila Times
Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals secures covenant waiver By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals secures covenant waiver - Investing.com India
Common Warts Market to Expand Significantly by 2034, States - openPR
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Verrica reports high response rate in skin cancer study - MSN
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MyChesCo
HPV Induced Cutaneous Tumors Market Revenue to Expand - openPR
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Genital Warts Market Size to Reach USD 1,435.0 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Barclays PLC Grows Stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders - Simply Wall St
Verrica Showcases Promising VP-315 Data at Dermatology Conference - MyChesCo
New Data Suggest Potential of VP-315 as Treatment for Basal Cell Carcinoma - MD Magazine
Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire
Verrica reports high response rate in skin cancer study By Investing.com - Investing.com Canada
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):